Carding et al. (2024)
- Authors: Simon Carding, DISCOVER-ME Consortium
- Institutes: Quadram Institute Bioscience, Norwich, UK, University of East Anglia, UK, European Horizon Europe Health Cluster
- Publisher: European Commission
- Link: DOI
Summary
This project represents the first major, multi-million euro commitment from the EU specifically targeting the biological stratification of ME/CFS patients. By using high-resolution ‘omics’ technologies across a large international cohort, the study aims to finally move past the ‘one size fits all’ approach. This effort is expected to enable the discovery of distinct disease subtypes and the first reliable diagnostic biomarkers for the condition.
What was researched?
The DISCOVER-ME project is a large-scale international research initiative focused on identifying biological subgroups (stratification) and diagnostic biomarkers in patients with ME/CFS.
Why was it researched?
It was launched to address the critical lack of objective diagnostic tests and the high biological complexity of the patient population, which has historically hindered the development of effective treatments.
How was it researched?
A consortium of 21 international partners utilizes multi-disciplinary ‘omics’ approaches, including genetics, proteomics, and metabolomics, to analyze a massive, well-characterized patient cohort. The project is funded with €7.5 million through the EU’s Horizon Europe program.
What has been found?
As a recently launched initiative, the project aims to identify distinct molecular signatures that distinguish ME/CFS from other fatiguing illnesses. Researchers expect to define specific patient clusters that may respond to different targeted therapies.
Discussion
The study’s unprecedented scale and funding are significant strengths for the field. However, researchers emphasize that success depends heavily on high-quality, standardized biobanking and the ability to find clear biological signals within a highly heterogeneous population.
Conclusion & Future Work
The project is expected to provide a comprehensive biological map of ME/CFS. This foundation will likely underpin the development of future diagnostic tools and personalized medical interventions.